Miltefosine

Drug Profile

Miltefosine

Alternative Names: D 18506; HePC; Hexadecylphosphocholine; HPC; Impavido; Miltefosin; Miltex

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Baxter Oncology; Zentaris
  • Developer AEterna Zentaris GmbH; Knight Therapeutics; MegaPharm Ltd; Profounda
  • Class Antineoplastics; Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Encephalitis; Acanthamoeba infections; Visceral leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis
  • Preclinical Acanthamoeba infections
  • No development reported Chagas disease
  • Discontinued Malignant melanoma

Most Recent Events

  • 28 Jun 2017 Miltefosine receives Orphan Drug status for Granulomatous amebic encephalitis in USA
  • 19 Dec 2016 Preclinical trials in Acanthamoeba infections in USA (unspecified route)
  • 19 Dec 2016 Miltefosine receives Orphan Drug status for Acanthamoeba keratitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top